Study population baseline characteristics
. | Patients with PHI . | Patients with CHI . | LTNP patients . |
|---|---|---|---|
| No. patients | 41 | 40 | 7 |
| Median age, y (range) | 32 (17-53) | 43 (30-79) | 42 (36-47) |
| Median CD4+ T-cell counts (range) | 645 (204-1412) | 591 (68-850) | 736 (520-908) |
| Median HIV RNA, log10 copies/mL (range) | 4.57 (2.69-5.46) | 2.28 (1.7-4.5) | 2.49 (1.7-3.34) |
| Median time from ARS, d (range) | 32 (10-84) | NA | NA |
| Duration of HIV infection | 3 mo | ≥ 7 y | ≥ 10 y |
| ART | Yes | Yes | No |
. | Patients with PHI . | Patients with CHI . | LTNP patients . |
|---|---|---|---|
| No. patients | 41 | 40 | 7 |
| Median age, y (range) | 32 (17-53) | 43 (30-79) | 42 (36-47) |
| Median CD4+ T-cell counts (range) | 645 (204-1412) | 591 (68-850) | 736 (520-908) |
| Median HIV RNA, log10 copies/mL (range) | 4.57 (2.69-5.46) | 2.28 (1.7-4.5) | 2.49 (1.7-3.34) |
| Median time from ARS, d (range) | 32 (10-84) | NA | NA |
| Duration of HIV infection | 3 mo | ≥ 7 y | ≥ 10 y |
| ART | Yes | Yes | No |
Data in the table are expressed as median (range)
PHI indicates primary HIV infection; CHI, chronic HIV infection; LTNP, long-term nonprogressors; ARS, antiretroviral syndrome; ART, antiretroviral therapy; and NA, not available